Is Ipamorelin Legal in the UK and UAE?
Ipamorelin is not a UK controlled substance but is prohibited under the WADA Prohibited List, and has no MHRA marketing authorisation — lawful as a research reagent, not lawful to market for human growth-hormone use.
Ipamorelin is not scheduled as a controlled substance in the UAE and is available only through the research-reagent channel, with no MOHAP/DHA clinical authorisation.
UK detail
Ipamorelin, a selective growth-hormone secretagogue, sits outside the Misuse of Drugs Act schedules but is on the WADA Prohibited List, relevant to anyone tested under UK Anti-Doping rules. It has never received a UK marketing authorisation, so the same Human Medicines Regulations 2012 restriction on human-use marketing applies as with CJC-1295.
UAE detail
Ipamorelin is not scheduled in the UAE. It is supplied research-use-only; clinical growth-hormone treatment in the UAE runs through DHA/MOHAP-licensed prescribers using authorised pharmaceutical products, a separate route entirely.
This is a general overview, not legal advice, and law in this area can change. For a specific situation, consult a solicitor with life-sciences regulatory experience (UK) or MOHAP/DHA directly (UAE). See our full UK compliance guide and UAE compliance guide for the full legal framework this page summarises.